Ganirelix dosing & administration
Fast-acting GnRH antagonist that stops premature ovulation during fertility treatment
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much do I take?
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
250 mcg
Frequency
Once daily during the mid-to-late follicular phase
Duration
Continued daily until the day of hCG administration (typically about 5-9 days)
FDA-labeled dose for inhibiting premature LH surges during controlled ovarian stimulation; started after several days of FSH and continued until hCG trigger [4].
Timing
Best time to take
Administer Ganirelix at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
With food?
Ganirelix injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
If stacking
Ganirelix should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting your dose
Increase if
- You've tolerated the current dose for the recommended period without significant side effects
- Therapeutic goals haven't been met at the current dose level
- Your healthcare provider recommends dose escalation based on your response
- Lab work or clinical assessments support a higher dose
Decrease if
- Side effects are bothersome or impacting daily life despite management strategies
- You experience any signs of an adverse reaction
- Lab results indicate the need for dose reduction
- Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- Therapeutic goals being met with minimal side effects
- Stable and consistent response to treatment
- Lab values or clinical markers trending in the right direction
- Good tolerance with manageable or absent side effects
Administration
How do I use it?
Reconstitution
What you need
Injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Storage
Before reconstitution
Store Ganirelix in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
After reconstitution
Once reconstituted, Ganirelix should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation — discard the vial
Sample daily schedule
As prescribed (once daily)
As prescribed by your healthcare provider injection
Site: Subcutaneous injection—rotate sites if applicable
Maintain a consistent schedule for optimal results with Ganirelix. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.
Safety
Is it safe?
Side effects
Commonly reported: Mild discomfort at treatment site, Injection site reactions (redness, bruising, swelling), Headaches, Abdominal pain, Pelvic discomfort, Nausea, Fatigue or dizziness
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Ganirelix
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Ganirelix should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Flagged pairings
- Other GnRH antagonists (like cetrorelix) in the same cycle — Use with caution—discuss with your healthcare provider.
- Certain herbal supplements that affect hormones — Use with caution—discuss with your healthcare provider.
Published research
What the studies show
Mouanness M, et al. · 2025
Comparative study of ganirelix and other GnRH antagonists shows ganirelix achieves comparable LH suppression and IVF outcomes to modern alternatives. Over 10,000 patients have safely used ganirelix in controlled trials, establishing it as a gold standard for ovulation control.
Glujovsky D, et al. · 2023
Meta-analysis confirming GnRH antagonists including ganirelix provide excellent LH surge prevention with little or no difference in oocyte retrieval cancellation compared to alternative hormonal approaches.
Qi Q, et al. · 2023
Ganirelix-based combination therapy significantly reduces moderate and severe OHSS incidence to 20.5% versus 42.3% in high-risk women, while maintaining excellent cumulative live birth rates of 74.4%.
U.S. Food and Drug Administration · 2024
FDA label: ganirelix acetate 250 mcg is administered subcutaneously once daily during the mid-to-late follicular phase to inhibit premature LH surges in women undergoing controlled ovarian stimulation; continued daily until the day of hCG administration.
Head to head
Ganirelix compared
Want the full picture?
The complete Ganirelix research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.